Long-term supaglutide therapy resulted in reduced hyperglycemia, ameliorated obesity and improved lipid metabolism implying its anti-diabetic cardiac benefits, in accord with the clinical evidence that GLP-1 therapy revealed beneficial effects in cardiac dysfunction (Du et al., 2016; Marso et al., 2016a,b). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.